![](/img/cover-not-exists.png)
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study
Stroes, Charlotte I., Schokker, Sandor, Creemers, Aafke, Molenaar, Remco J., Hulshof, Maarten C.C.M., van der Woude, Stephanie O., Bennink, Roel J., Mathôt, Ron A.A., Krishnadath, Kausilia K., Punt, CJournal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.19.01814
Date:
December, 2019
File:
PDF, 934 KB
2019